Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05686798 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Oct 2025 to Jan 2027
    • Study completion date: Oct 2026 to Dec 2027
    • Site contact updated
    v5
  2. Primary completion date: Oct 2024 to Oct 2025
    • Study completion date: Oct 2024 to Oct 2026
    v4
  3. Re-verified, no change to tracked fieldsv3
  4. Primary completion date: Oct 2023 to Oct 2024v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Henry Ford Health System
91 trials monitored
See 3 trials at risk
Glioma
1,251 trials monitored
See 88 trials at risk
Glioblastoma
710 trials monitored
See 52 trials at risk
The primary goal of this Phase I study is to determine the maximum tolerated dose of oncolytic adenovirus mediated double suicide-gene therapy in combination with fractionated stereotactic radiosurgery in patients with recurrent high-grade astrocytoma undergoing resection.
Trial Details
NCT Number NCT05686798
Lead Sponsor Henry Ford Health System
Conditions
(from sponsor)		 Malignant Glioma of Brain, Astrocytoma, Malignant Astrocytoma, Brain Tumor, Glioma, Brain Cancer, Glioblastoma, Glioblastoma Multiforme +1 more
Related terms Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma
Enrollment 18 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov